SCHEMBL540215

SCHEMBL540215

O=C1c2cnc3[nH]ncc3c2C(=O)N1CCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.47
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
GAA P10253 2/20 0.45
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SLC29A1 Q99808 1/20 0.43
CYP1B1 Q16678 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 2/20 0.40
APAF1 O14727 1/20 0.40
CASP1 P29466 1/20 0.40
BLM P54132 1/20 0.40
CASP7 P55210 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PARK7 Q99497 2/20 0.40
ALDH2 P05091 1/20 0.40
ALDH3A1 P30838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13145073 0.90 SLC29A1 (0.41) CASP3ALDH1A1MAPTRAB9AGAA
SCHEMBL2816972 0.89 GRM5 (0.41) CASP3ALDH1A1MAPTRAB9AGAA
SCHEMBL2819102 0.88 GRIN2B (0.41) ALDH1A1SMN1; SMN2TDP1GRIN2BADRA1D
SCHEMBL2815188 0.88 CA1 (0.42) CASP3ALDH1A1MAPTRAB9AGAA
SCHEMBL2817826 0.87 L3MBTL1 (0.44) ALDH1A1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2820930 0.87 CYP1A2 (0.46) ALDH1A1MAPTRAB9AGAAKDM4E
SCHEMBL2815674 0.87 NUDT1 (0.42) ALDH1A1MAPTRAB9AGAAKDM4E
SCHEMBL2817148 0.85 GSK3A (0.45) ALDH1A1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL2872871 0.85 SLC29A1 (0.40) CASP3ALDH1A1GAAKDM4ESMN1; SMN2
SCHEMBL2815478 0.85 HSD17B10 (0.59) ALDH1A1MAPTRAB9AKDM4ECYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414357-A1 PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114904-A1 PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ARQULE, INC. (US) 2010-10-07 WO claimed
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
EP-2414357-A1 PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ArQule, Inc. (US) 2012-02-08 EP disclosed
WO-2010114904-A1 PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ARQULE, INC. (US) 2010-10-07 WO disclosed
WO-2010114904-A1 PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS MKI67, TP53, PDK1 CASP3 1117/4885ALDH1A1 1053/4885MAPT 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.